Scholar Rock Holding Corp (SRRK) Stock AnalysisSRRKScholar Rock Holding Corp

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Scholar Rock Holding Corp (SRRK) is currently not a strong buy due to its recent price decline and negative financial indicators. The current price is $39.90, with a 5-day change of -5.43% and a 20-day change of -14.47%. The RSI is at 24.002, indicating it is in oversold territory, which could suggest a potential rebound. However, the company has reported significant net losses, with a net income of -$109,896,000 in Q2 2026, and a forward P/E ratio of 0, indicating no earnings expectations. The main risk is the ongoing negative sentiment reflected in the stock's recent performance and the uncertainty around the uptake of its newly approved drug, ISEMBYLD, which has a market reaction that remains cautious. Therefore, while there are positive catalysts like FDA approval, the financial health and current price trends suggest holding off on new purchases for now.

4 analysts cover SRRK: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.